Skip to main content
. 2021 Dec 13;12:736860. doi: 10.3389/fphar.2021.736860

FIGURE 3.

FIGURE 3

Acceptability curves comparing the cost-effectiveness of nivolumab plus cabozantinib vs. sunitinib strategies for patients with advanced renal cell carcinoma. CE, cost effectiveness..